{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kang EY"],"funding":["Alberta Precision Laboratories","Cancer Research UK","NCATS NIH HHS","NCRR NIH HHS","Medical Research Council","National Cancer Institute","NCI NIH HHS"],"pagination":["697-713"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10107112"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["129(5)"],"pubmed_abstract":["<h4>Background</h4>Cyclin E1 (CCNE1) is a potential predictive marker and therapeutic target in tubo-ovarian high-grade serous carcinoma (HGSC). Smaller studies have revealed unfavorable associations for CCNE1 amplification and CCNE1 overexpression with survival, but to date no large-scale, histotype-specific validation has been performed. The hypothesis was that high-level amplification of CCNE1 and CCNE1 overexpression, as well as a combination of the two, are linked to shorter overall survival in HGSC.<h4>Methods</h4>Within the Ovarian Tumor Tissue Analysis consortium, amplification status and protein level in 3029 HGSC cases and mRNA expression in 2419 samples were investigated.<h4>Results</h4>High-level amplification (>8 copies by chromogenic in situ hybridization) was found in 8.6% o"],"journal":["Cancer"],"pubmed_title":["CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study."],"pmcid":["PMC10107112"],"funding_grant_id":["R21 CA210210","R01 CA243511","R01CA172404","U01 CA243483","UL1 TR000124","RS17‐601, RS10‐526","P30 CA008748","K07 CA080668","22905","R01 CA243483","R01 CA160669","P30 CA071789","N01 CA015083","P30 CA014089","P30 CA047904","R01 CA172404","R01 CA122443","R01 CA248288","P50 CA136393","P30 CA015083","15601","M01 RR000056","R01 CA095023","MC_UU_00004/01"],"pubmed_authors":["Heitz F","Shah M","Kobel M","Harnett PR","Boros J","Lubinski J","Hogdall CK","Cohen PA","Olbrecht S","Mohan GR","Gronwald J","Brucker SY","van-Wagensveld L","Alsop J","Gentry-Maharaj A","Khabele D","El-Bahrawy MA","Shvetsov YB","Jones ME","Salfinger SG","Courtney-Brooks M","Crowe P","Rodriguez-Antona C","Staebler A","Berger J","Toloczko A","Van Gorp T","Orsulic S","Lester J","Ryan A","Palacios J","Fischer A","Jewell A","Bolithon A","Modugno F","Neuhausen SL","Heikaus S","Madan R","Jimenez-Linan M","Hein A","Pearce CL","Popovic G","Karlan BY","Heublein S","Gayther SA","Meagher NS","Vierkant RA","Talhouk A","Tang K","Benitez J","Conrads TP","Horlings HM","Sundfeldt K","Hendley J","Van Nieuwenhuysen E","Loverix L","Huntsman DG","Schildkraut JM","Candido Dos Reis FJ","Coulson P","Riggan MJ","Garcia MJ","Huzarski T","Olawaiye A","Goodman MT","Wilkens LR","Bosmuller H","Lambrechts D","Hogdall E","van der Aa MA","Bowtell DD","Lee CH","Stewart CJR","Wu AH","Grube M","Taylor SE","Farrington K","Cybulski C","Erber R","Traficante N","Kennedy CJ","Wang C","Bisinotto C","Linder A","Pharoah PDP","Kruitwagen RFPM","Millstein J","Pike MC","Harter P","Swerdlow AJ","Winham SJ","Singh N","Lambie N","Kaufmann SH","Barlow E","Quinn CM","Sinn HP","Schoemaker MJ","Sharma R","Fereday S","Maxwell GL","Steele L","Fasching PA","Ataseven B","Tan A","Nelson GS","Sasamoto N","Carney ME","Hecht JL","Van de Vijver KK","Hernandez BY","Kommoss FKF","Brooks-Wilson A","Berchuck A","Leung B","Le ND","Farrell R","Cook LS","Terry KL","Darcy KM","AOCS Group","Weir A","Hirasawa A","Ghatage P","Menon U","Polo SH","Brand AH","Kommoss S","Beckmann MW","Harrington SP","Ramus SJ","Cunningham JM","Sonke GS","DeFazio A","Cramer DW","Cazorla-Jimenez A","Gilks CB","Hartmann A","Vergote I","Ruebner M","Brenton JD","Elishaev E","Casablanca Y","Kang EY","Anglesio MS","Leung Y","Lener M","Goode EL"],"additional_accession":[]},"is_claimable":false,"name":"CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.","description":"<h4>Background</h4>Cyclin E1 (CCNE1) is a potential predictive marker and therapeutic target in tubo-ovarian high-grade serous carcinoma (HGSC). Smaller studies have revealed unfavorable associations for CCNE1 amplification and CCNE1 overexpression with survival, but to date no large-scale, histotype-specific validation has been performed. The hypothesis was that high-level amplification of CCNE1 and CCNE1 overexpression, as well as a combination of the two, are linked to shorter overall survival in HGSC.<h4>Methods</h4>Within the Ovarian Tumor Tissue Analysis consortium, amplification status and protein level in 3029 HGSC cases and mRNA expression in 2419 samples were investigated.<h4>Results</h4>High-level amplification (>8 copies by chromogenic in situ hybridization) was found in 8.6% o","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Mar","modification":"2026-03-31T11:52:13.207Z","creation":"2025-04-06T18:37:32.711Z"},"accession":"S-EPMC10107112","cross_references":{"pubmed":["36572991"],"doi":["10.1002/cncr.34582"]}}